
Vantictumab Combination Benefits Patients with Stage IV Pancreatic Cancer
Audio Journal of Oncology COPENHAGEN, Denmark—In a phase 1b study patients with previously untreated stage IV pancreatic cancer responded or derived “clinical benefit” from a regimen in wh
Audio Journal of Oncology
COPENHAGEN, Denmark—In a phase 1b study patients with previously untreated stage IV pancreatic cancer responded or derived “clinical benefit” from a regimen in which a Wnt-signaling inhibitor—the humanized monoclonal antibody vantictumab—was added to nab-paclitaxel and gemcitabine chemotherapy. Colin Weekes MD PhD, Associate Professor at the University of Colorado in Denver, who reported findings from the trial at the 2016 European Society for Medical Oncology (ESMO) congress, discusses their clinical implications with Peter Goodwin. Debashis Sarker MD FRCP, Senior Lecturer and Consultant in Medical Oncology, at Guy’s, St Thomas’ and King’s College Hospitals, London, who was not involved with the study.
Tags
Next in ESMO 2016
All 9 interviewsInterview 7 of 9

Niraparib Quadruples Progression Free Survival in Platinum-Sensitive Ovarian Cancer
COPENHAGEN, Denmark—Marked prolongation of progression free survival (PFS) in all groups of patients with platinum-sensitive recurrent ovarian cancer was reported at the European Society for Medical O
Related Episodes

Preoperative Chemoradiotherapy Extends Survival in Pancreatic Cancer
CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved ou

ASCO Audio Journal of Oncology – August 1st 2006
John Neoptolemos Wilko Weichert Christophe Nemos Pancreatic Cancer: Adjuvant Chemotherapy Improves Outlook for Patients with Resectable Tumors – ESPAC Trial Results REFERENCE: National Cancer Re

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer
MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after first line chemo-immunotherapy induction. Results from the phase 3 DeLLphi-305 trial were reported at the 2026 Annual Congress of the European Society for Medical Oncology showing significantly improved overall and progression-free survival. Peter Goodwin spoke with study author Jacob Sands MD, Associate Chief of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in Boston, USA, and Assistant Professor of Medicine at Harvard Medical School: